<DOC>
	<DOCNO>NCT02633020</DOCNO>
	<brief_summary>Protocol CELIM-RCD-002 design Phase 2a randomize , double-blind , placebo-controlled , parallel group study evaluate efficacy safety AMG 714 treatment adult patient Type II Refractory Celiac Disease ( RCD-II ) , situ small bowel T cell lymphoma .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety AMG 714 Adult Patients With Type II Refractory Celiac Disease</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>Confirmed diagnosis refractory celiac disease Type 2 ( RCDII ) Greater 20 % aberrant intraepithelial lymphocyte ( IEL ) assess flow cytometry On glutenfree diet least 6 month Avoid pregnancy EnteropathyAssociated T cell Lymphoma ( EATL ) Infections Immune suppression Clinically significant comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>